Literature DB >> 10071990

The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery.

K E Raby1, S J Brull, F Timimi, S Akhtar, S Rosenbaum, C Naimi, A D Whittemore.   

Abstract

UNLABELLED: Patients undergoing vascular surgery have a high risk of suffering major postoperative cardiac events. Preoperative myocardial ischemia as detected by Holter monitoring identifies a high-risk subgroup whose postoperative ischemia, similarly detected, seems to herald major cardiac events. In this study, we determined whether systematic, patient-specific postoperative heart rate control with beta-adrenergic blocker therapy decreases the incidence of postoperative ischemia among high-risk vascular surgery patients. A total of 26 of 150 patients who underwent elective vascular surgery and were monitored preoperatively by 24-h Holter were found to have significant myocardial ischemia as defined by ST-segment depression. The minimal heart rate at which this ST-segment depression occurred was identified (ischemic threshold), and these 26 patients were then randomized to receive continuous i.v. beta-blockade with esmolol or placebo plus usual medical therapy, aiming to reduce the postoperative heart rate to 20% below the ischemic threshold. All patients were monitored by Holter for 48 h postoperatively. Postoperative Holter readings were analyzed for the incidence of ischemia and for the number of hours during which heart rate was controlled below the ischemia threshold. Patients had a median of two episodes of preoperative ischemia lasting a median of 30 min (range 1-155 min). A total of 15 patients were randomized to receive esmolol, and 11 were randomized to receive placebo. The two groups were comparable with respect to clinical characteristics and incidence and duration of preoperative ischemia. Ischemia persisted in the postoperative period in 8 of 11 placebo patients (73%), but only 5 of 15 esmolol patients (33%) (P < 0.05). Of the 15 esmolol patients, 9 had mean heart rates below the ischemic threshold, and all 9 had no postoperative ischemia. A total of 4 of 11 placebo patients had mean heart rates below the ischemic threshold, and 3 of the 4 had no postoperative ischemia. There were two postoperative cardiac events among patients who had postoperative ischemia (one placebo, one esmolol) and whose mean heart rates exceeded the ischemic threshold. Our data suggest that patient-specific, strict heart rate control aiming for a predefined target based on individual preoperative ischemic threshold was associated with a significant reduction and frequent elimination of postoperative myocardial ischemia among high-risk patients and provide a rationale for a larger trial to examine this strategy's effect on cardiac risk. IMPLICATIONS: Patients who undergo peripheral vascular surgery often experience transient cardiac complications and/or permanent heart damage just after surgery because of inadequate myocardial blood flow. In this study, we identified patients at high risk of cardiac complications after vascular surgery and showed that if their heart rate was carefully controlled for 48 h after surgery, myocardial ischemia, a common marker of heart injury, was markedly reduced.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071990     DOI: 10.1097/00000539-199903000-00002

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  25 in total

Review 1.  [Perioperative beta-receptor blockade. For and against].

Authors:  B Preckel; M Poels; F Wappler; W Schlack; W Buhre
Journal:  Anaesthesist       Date:  2010-07       Impact factor: 1.041

Review 2.  [Strategies for perioperative sympatho-modulation].

Authors:  J Wacker; T Pasch; M C Schaub; M Zaugg
Journal:  Anaesthesist       Date:  2005-04       Impact factor: 1.041

Review 3.  How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials.

Authors:  P J Devereaux; W Scott Beattie; Peter T-L Choi; Neal H Badner; Gordon H Guyatt; Juan C Villar; Claudio S Cinà; Kate Leslie; Michael J Jacka; Victor M Montori; Mohit Bhandari; Alvaro Avezum; Alexandre B Cavalcanti; Julian W Giles; Thomas Schricker; Homer Yang; Carl-Johan Jakobsen; Salim Yusuf
Journal:  BMJ       Date:  2005-07-04

4.  Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing non-cardiac surgery.

Authors:  Hermann Blessberger; Sharon R Lewis; Michael W Pritchard; Lizzy J Fawcett; Hans Domanovits; Oliver Schlager; Brigitte Wildner; Juergen Kammler; Clemens Steinwender
Journal:  Cochrane Database Syst Rev       Date:  2019-09-26

5.  Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.

Authors:  Günther Krumpl; Ivan Ulc; Michaela Trebs; Pavla Kadlecová; Juri Hodisch
Journal:  Eur J Clin Pharmacol       Date:  2017-01-13       Impact factor: 2.953

Review 6.  New-onset atrial fibrillation: an update.

Authors:  Takeshi Omae; Eiichi Inada
Journal:  J Anesth       Date:  2018-03-09       Impact factor: 2.078

Review 7.  Value and limitations of ambulatory ECG monitoring for assessment of myocardial ischemia.

Authors:  D Tzivoni
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-07       Impact factor: 1.468

Review 8.  [Perioperative pharmacological myocardial protection. Systematic literature-based process optimization].

Authors:  M Petzoldt; J Kähler; A E Goetz; P Friederich
Journal:  Anaesthesist       Date:  2008-07       Impact factor: 1.041

Review 9.  [Premedication visits. Economizing at the cost of the patient?].

Authors:  C D Kratz; M Christ; B Maisch; K M Kerwat; C Olt; A Zielke; A Hellinger; H Wulf; G Geldner
Journal:  Anaesthesist       Date:  2004-09       Impact factor: 1.041

10.  Prophylactic beta-blockade to prevent myocardial infarction perioperatively in high-risk patients who undergo general surgical procedures.

Authors:  Rebecca C Taylor; Giuseppe Pagliarello
Journal:  Can J Surg       Date:  2003-06       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.